What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Recombinant MICB Protein Expression: A Practical Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Recombinant MICB Protein Expression

MICB (MHC class I polypeptide-related sequence B) is a stress-induced transmembrane glycoprotein encoded by the MICB gene located on human chromosome 6p21.33, within the major histocompatibility complex (MHC) class I region. Unlike classical MHC class I molecules, MICB does not associate with β2-microglobulin or present peptide antigens. Instead, it functions as a ligand for the activating receptor NKG2D (natural killer group 2 member D), which is expressed on natural killer (NK) cells, CD8⁺ αβ T cells, and γδ T cells. Under normal physiological conditions, MICB expression is low or absent on most healthy cells. However, cellular stress—including DNA damage, heat shock, viral infection, and oncogenic transformation—upregulates MICB transcription, leading to surface presentation and subsequent immune recognition and elimination of stressed or transformed cells.

Biological Function of MICB

The interaction between MICB and NKG2D triggers a activating signaling cascade in effector lymphocytes. Upon ligand engagement, NKG2D associates with the adaptor protein DAP10, which contains an immunoreceptor tyrosine-based activation motif (ITAM)-like YxxM motif. This leads to phosphatidylinositol 3-kinase (PI3K) recruitment and downstream activation of NK cell cytotoxicity and T cell co-stimulation. The MICB–NKG2D axis constitutes a critical component of innate immune surveillance against tumors and intracellular pathogens. Notably, many tumors evade this surveillance by shedding soluble MICB from the cell surface through proteolytic cleavage by matrix metalloproteinases (MMPs) or ADAM (a disintegrin and metalloproteinase) family enzymes. Soluble MICB (sMICB) in the serum downregulates NKG2D surface expression on effector cells, impairing antitumor immunity.

Applications of Recombinant MICB

Recombinant MICB protein is an essential reagent for multiple research and translational applications. First, purified recombinant MICB is used to study the molecular basis of NKG2D–MICB interactions through surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and co-crystallization studies. Second, recombinant MICB serves as a standard for quantitative ELISA development to measure sMICB levels in patient serum, which has prognostic value in various cancers. Third, recombinant MICB can be used to generate monoclonal antibodies for diagnostic and therapeutic purposes. Fourth, MICB–Fc fusion proteins are employed as tools to block NKG2D signaling in vitro and in vivo, enabling functional studies of the NKG2D pathway. Finally, recombinant MICB is used in immunization protocols to raise polyclonal antisera for immunohistochemistry and flow cytometry applications.

The production of recombinant MICB requires careful selection of an expression system, construct design, and purification strategy. This guide provides a systematic overview of the practical considerations for expressing recombinant MICB protein, from vector design through quality control.

Choosing an Expression System for MICB

The choice of expression host is the most consequential decision in recombinant protein production. For MICB, the major options are bacterial (Escherichia coli) and mammalian cell systems. Each has distinct advantages and limitations that must be weighed against the intended application of the final protein.

E. coli Expression

E. coli remains the most widely used host for recombinant protein expression due to its rapid growth, high cell density, well-characterized genetics, and low cost. For MICB, the extracellular domain (ECD) comprising the α1 and α2 domains (approximately amino acids 1–276 of the mature protein) is the most commonly expressed region, as it contains the NKG2D-binding interface.

Advantages:

High yield potential (typically 10–100 mg/L of culture)
Fast generation time (doubling time ~20 minutes)
Simple and inexpensive culture media
Extensive availability of expression vectors and host strains

Limitations:

Lack of post-translational modifications (MICB is normally glycosylated at three N-linked sites: N102, N205, and N236 in the ECD)
Formation of inclusion bodies when expressed at high levels or at elevated temperatures
Endotoxin contamination from the outer membrane lipopolysaccharide (LPS)
Possible improper disulfide bond formation (MICB ECD contains four conserved cysteine residues forming two disulfide bonds)

For applications requiring unglycosylated protein—such as X-ray crystallography or NMR spectroscopy—E. coli expression is often preferred because glycan heterogeneity can impede crystallization. However, if the protein is intended for cell-based assays or therapeutic development, the lack of glycosylation may affect folding, stability, or receptor binding affinity.

Mammalian Cell Expression

Mammalian expression systems, particularly Chinese hamster ovary (CHO) cells and human embryonic kidney (HEK) 293 cells, are the preferred choice when post-translational modifications are required for proper function.

Advantages:

Correct folding and disulfide bond formation
Authentic N-linked glycosylation
Proper signal peptide processing
Secretion of soluble protein into the culture medium
Low endotoxin levels

Limitations:

Lower yields compared to E. coli (typically 1–20 mg/L)
Higher cost of culture media and supplements
Longer production timelines (weeks vs. days)
More complex transfection and selection procedures

For recombinant MICB intended for functional studies involving NKG2D binding or for use as an immunogen, mammalian expression is generally recommended because the glycosylation pattern more closely resembles the native human protein. The choice between recombinant protein expression system options ultimately depends on the downstream application, required quantity, and budget constraints.

Feature	E. coli	Mammalian (HEK293/CHO)
Yield	10–100 mg/L	1–20 mg/L
Glycosylation	None	Complex N-linked
Disulfide bonds	Possible, but may misfold	Correct
Cost	Low	High
Timeline	3–5 days	2–4 weeks
Endotoxin	High	Low
Best for	Crystallography, NMR	Functional assays, therapeutics

Designing the MICB Expression Construct

The design of the expression construct determines whether recombinant MICB will be produced as a soluble secreted protein or as an intracellular inclusion body. Several elements must be considered: the signal peptide, the domain boundaries, affinity tags, and codon optimization.

Signal Peptide and Domain Selection

MICB is a type I transmembrane protein with an N-terminal signal peptide (amino acids 1–23 of the full-length precursor), an extracellular domain (amino acids 24–307), a transmembrane domain (amino acids 308–330), and a short cytoplasmic tail (amino acids 331–343). For recombinant expression of soluble MICB, the transmembrane and cytoplasmic domains are excluded, and the ECD is fused to a signal peptide to direct secretion.

For E. coli expression, the native human signal peptide is generally not recognized by the bacterial signal peptidase. Instead, the pelB leader sequence (from pectate lyase B of Erwinia carotovora) or the ompA signal peptide is commonly used to direct secretion to the periplasm, where oxidizing conditions permit disulfide bond formation. Alternatively, the protein can be expressed without a signal peptide in the cytoplasm, but this often results in inclusion body formation.

For mammalian expression, the native MICB signal peptide (MGLGPVFLFLLPLLPGTQ) is functional and should be retained. Alternatively, the human IgG kappa light chain signal peptide (METDTLLLWVLLLWVPGSTGD) is widely used and provides efficient secretion.

The ECD boundary should be defined carefully. The α1 and α2 domains form the NKG2D-binding platform, while the α3 domain (amino acids 205–307) is an immunoglobulin-like domain that stabilizes the structure. For most applications, expressing the full ECD (amino acids 24–307) is recommended. Truncation to only the α1α2 domains (amino acids 24–204) may increase yield but can reduce stability and binding affinity.

Affinity Tags and Protease Cleavage Sites

Affinity tags facilitate purification but may interfere with protein function or crystallization. The most common tag for recombinant MICB is the polyhistidine (His₆) tag, which binds to nickel-nitrilotriacetic acid (Ni-NTA) resin. The His₆ tag can be placed at either the N-terminus or C-terminus. For secreted proteins, a C-terminal His₆ tag is often preferred because the N-terminal signal peptide must be cleaved during secretion, and an N-terminal tag may be removed along with the signal peptide.

A typical construct for E. coli periplasmic expression is:

pelB signal peptide – MICB ECD (aa 24–307) – His₆

For mammalian expression:

Native MICB signal peptide – MICB ECD (aa 24–307) – His₆

A protease cleavage site between the protein and the tag allows removal of the tag after purification. Commonly used sites include:

TEV protease (tobacco etch virus): recognition sequence ENLYFQG, cleaves between Q and G
Thrombin: recognition sequence LVPRGS, cleaves between R and G
Factor Xa: recognition sequence IEGR, cleaves after R

The TEV protease site is preferred because TEV protease is highly specific and active at 4°C, reducing the risk of proteolytic degradation during cleavage.

Codon optimization is critical for E. coli expression. The human MICB gene has a GC content and codon usage pattern that differs significantly from E. coli. Codon-optimized synthetic genes, designed using software such as SnapGene or Benchling, can increase expression yields by 5–10 fold. For mammalian expression, codon optimization is less critical but can still improve expression levels.

Cloning and Transformation Strategies

Once the expression construct is designed, it must be assembled into an expression vector and introduced into the host cells.

Gateway Cloning vs. Traditional Cloning

Traditional restriction enzyme-based cloning involves digesting both the insert (PCR product or cDNA) and the vector with the same restriction enzymes, followed by ligation with T4 DNA ligase. For MICB, common restriction sites used are NheI (GCTAGC) and XhoI (CTCGAG), which are rarely present in the MICB coding sequence. The ligation reaction is typically performed at 16°C for 1–2 hours or at 4°C overnight, using a 3:1 molar ratio of insert to vector.

Gateway cloning (Invitrogen) uses site-specific recombination rather than restriction enzymes. The MICB coding sequence is flanked with attB sites and recombined into a donor vector (pDONR221) to create an entry clone, which is then recombined into a destination vector containing the desired expression elements. Gateway cloning is more efficient and directional than traditional cloning, but requires specific vectors and enzymes (BP Clonase and LR Clonase).

For most undergraduate and routine laboratory applications, traditional restriction cloning is sufficient and more cost-effective. The key steps are:

PCR amplification of the MICB ECD from a cDNA template (e.g., human spleen cDNA library) using primers that incorporate restriction sites at the 5' and 3' ends. Use a high-fidelity polymerase such as Phusion or Q5 with an extension time of 30 seconds per kilobase. Perform 25–30 cycles with an annealing temperature 3°C above the primer melting temperature.
Restriction digestion of both the PCR product and the vector (e.g., pET-28a for E. coli or pcDNA3.4 for mammalian expression) with the appropriate enzymes. Digest at 37°C for 1–2 hours, then heat-inactivate at 65°C for 20 minutes (for most enzymes) or purify by gel extraction.
Ligation using T4 DNA ligase at 16°C for 1 hour. Use approximately 100 ng of vector and a 3:1 molar excess of insert.
Transformation of the ligation product into competent E. coli cells (e.g., DH5α for plasmid propagation). Heat-shock transformation: incubate cells with DNA on ice for 30 minutes, heat-shock at 42°C for 45 seconds, recover in SOC medium at 37°C for 1 hour, then plate on selective agar (e.g., kanamycin at 50 µg/mL for pET-28a).

Verification by Sequencing

After transformation, individual colonies are picked and grown in liquid culture, and plasmid DNA is isolated using a miniprep kit. The presence of the MICB insert is confirmed by restriction digestion (checking for the expected fragment sizes) and, critically, by Sanger sequencing. Sequencing should cover the entire MICB coding region and the junctions with the vector to ensure no mutations were introduced during PCR. At least two independent clones should be sequenced to exclude PCR-induced errors.

Induction and Expression Optimization

Optimizing IPTG Concentration

For E. coli expression using the T7 promoter system (e.g., pET vectors), protein expression is induced by isopropyl β-D-1-thiogalactopyranoside (IPTG), a non-metabolizable analog of lactose. IPTG binds the lac repressor, releasing it from the operator and allowing T7 RNA polymerase transcription.

The optimal IPTG concentration varies between constructs and strains. A typical starting point is 0.1–1.0 mM IPTG. Lower concentrations (0.1–0.5 mM) often produce higher yields of soluble protein because the rate of protein synthesis is reduced, allowing more time for proper folding. Higher concentrations (1 mM) may drive faster expression but increase inclusion body formation.

The induction protocol for MICB in E. coli BL21(DE3) is:

Grow cells in LB medium containing the appropriate antibiotic at 37°C with shaking (200–250 rpm) until the optical density at 600 nm (OD₆₀₀) reaches 0.6–0.8 (mid-log phase).
Cool the culture to the induction temperature (typically 16–25°C for soluble expression).
Add IPTG to the desired final concentration (e.g., 0.5 mM).
Continue incubation for 4–16 hours. Lower temperatures require longer induction times.

Temperature is the most critical variable for soluble expression. At 37°C, MICB ECD is predominantly produced as inclusion bodies. Reducing the temperature to 16–20°C slows protein synthesis and promotes correct folding. A typical optimization matrix would test 16°C, 20°C, and 25°C with IPTG concentrations of 0.1, 0.5, and 1.0 mM, sampling at 4, 8, and 16 hours post-induction.

Mammalian Transfection Methods

For mammalian expression, the construct is introduced into HEK293 or CHO cells by transfection. The most common methods are:

Polyethylenimine (PEI): PEI (25 kDa linear, 1 mg/mL) is mixed with plasmid DNA at a 3:1 ratio (PEI:DNA, w/w) in serum-free medium, incubated for 15–20 minutes at room temperature, then added dropwise to cells. This method is inexpensive and suitable for large-scale production.
Lipofectamine 3000: A cationic lipid reagent that provides higher transfection efficiency but at greater cost. Follow the manufacturer's protocol, typically using 1–2 µg DNA per 10⁶ cells.
Calcium phosphate: DNA is mixed with CaCl₂ and added dropwise to phosphate-buffered saline (PBS) to form a precipitate that is taken up by cells. This method is less efficient but very economical.

For transient expression in HEK293 suspension cultures, PEI transfection is the standard approach. Cells are grown in serum-free medium (e.g., FreeStyle 293) at 37°C, 8% CO₂, with shaking at 120 rpm. At a cell density of 1–2 × 10⁶ cells/mL, the DNA–PEI complex is added, and the culture is maintained for 4–6 days. The recombinant MICB is secreted into the culture supernatant, which is harvested by centrifugation at 4,000 × g for 20 minutes.

For stable expression, the vector must include a selectable marker (e.g., neomycin resistance for G418 selection). After transfection, cells are cultured in medium containing G418 (400–800 µg/mL) for 2–3 weeks, and resistant colonies are screened for MICB expression by ELISA or Western blot.

Purification of Recombinant MICB

Affinity Chromatography

The first purification step for His-tagged MICB is immobilized metal affinity chromatography (IMAC) using Ni-NTA resin. The principle is the coordination of histidine residues with Ni²⁺ ions immobilized on the resin.

For E. coli periplasmic extracts or mammalian culture supernatants:

Clarify the sample: Centrifuge at 15,000 × g for 30 minutes at 4°C, then filter through a 0.45 µm membrane to remove debris.
Buffer exchange: If the sample is in a high-salt or complex medium, adjust to the binding buffer conditions. For Ni-NTA, the binding buffer is typically 50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole. Imidazole at 10–20 mM reduces non-specific binding without competing off the His-tagged protein.
Load the sample onto a pre-equilibrated Ni-NTA column (e.g., 1 mL resin per 5–10 mg of target protein) at a flow rate of 1 mL/min. Collect the flow-through for analysis.
Wash with binding buffer containing 20–50 mM imidazole to remove weakly bound contaminants. Use 10–20 column volumes.
Elute with elution buffer: 50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 250–500 mM imidazole. Collect 1 mL fractions and analyze by SDS-PAGE.

The eluted fractions containing MICB are pooled and concentrated using a centrifugal concentrator (e.g., Amicon Ultra-15, 10 kDa molecular weight cutoff).

Size-Exclusion Chromatography

Size-exclusion chromatography (SEC), also known as gel filtration, is used as a polishing step to remove aggregates, imidazole, and minor contaminants. SEC separates proteins based on hydrodynamic radius; larger proteins elute earlier.

A typical SEC protocol uses a Superdex 200 Increase 10/300 GL column (Cytiva) equilibrated with PBS (pH 7.4) or 20 mM HEPES, pH 7.5, 150 mM NaCl. The concentrated MICB sample (typically 1–2 mL at 5–10 mg/mL) is injected and run at 0.5 mL/min. MICB ECD (approximately 32 kDa for the unglycosylated form) should elute as a single symmetric peak. Aggregates elute in the void volume, and imidazole elutes near the total column volume.

SEC also serves as a quality control step: a monodisperse peak indicates a homogeneous, properly folded protein, while a broad or split peak suggests heterogeneity, aggregation, or degradation.

Characterization and Quality Control

SDS-PAGE and Coomassie Staining

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is the first-line method to assess the purity and molecular weight of recombinant MICB. Samples are mixed with reducing sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue), heated at 95°C for 5 minutes, and loaded onto a 12% polyacrylamide gel. Electrophoresis is performed at 120–150 V for 60–90 minutes.

After electrophoresis, the gel is stained with Coomassie Brilliant Blue R-250 (0.1% in 40% methanol, 10% acetic acid) for 30 minutes and destained in 40% methanol, 10% acetic acid until the background is clear. The expected molecular weight of recombinant MICB ECD with a His₆ tag is approximately 32–35 kDa for the unglycosylated form and 40–45 kDa for the glycosylated mammalian form. The higher molecular weight in mammalian expression reflects the addition of complex N-linked glycans.

Western Blot with Anti-MICB Antibodies

Western blotting confirms the identity of the purified protein. After SDS-PAGE, proteins are transferred to a polyvinylidene difluoride (PVDF) or nitrocellulose membrane using a wet transfer system at 100 V for 60 minutes in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol).

The membrane is blocked with 5% non-fat dry milk in Tris-buffered saline with Tween 20 (TBS-T: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. The primary antibody—a mouse monoclonal anti-MICB antibody (e.g., clone 236511, R&D Systems) used at 1:1,000 dilution—is incubated overnight at 4°C. After washing, a horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody (1:5,000) is applied for 1 hour at room temperature. The blot is developed with enhanced chemiluminescence (ECL) substrate and exposed to X-ray film or a digital imager.

Mass spectrometry provides the definitive confirmation of protein identity. The purified protein is digested with trypsin, and the resulting peptides are analyzed by LC-MS/MS. The peptide mass fingerprint should match the predicted MICB ECD sequence. Mass spectrometry also reveals the extent of glycosylation and any post-translational modifications.

Common Pitfalls and Troubleshooting

Inclusion Body Formation

The most frequent problem in E. coli expression of MICB is the formation of inclusion bodies—insoluble aggregates of misfolded protein. This occurs when the rate of protein synthesis exceeds the capacity of the cellular folding machinery.

Solutions:

Reduce induction temperature to 16°C or even 10°C
Reduce IPTG concentration to 0.1–0.2 mM
**Use a different E. coli strain** such as Rosetta (which supplies rare tRNAs) or Origami (which has mutations in thioredoxin reductase and glutathione reductase, promoting disulfide bond formation in the cytoplasm)
Co-express molecular chaperones such as GroEL/GroES or DnaK/DnaJ
Fuse MICB to a solubility-enhancing partner such as maltose-binding protein (MBP) or glutathione S-transferase (GST)

If inclusion bodies are unavoidable, they can be solubilized with 6–8 M urea or 6 M guanidine hydrochloride, followed by refolding by dialysis against a refolding buffer (e.g., 100 mM Tris-HCl, pH 8.0, 0.5 M arginine, 2 mM reduced glutathione, 0.2 mM oxidized glutathione). However, refolding yields are often low (5–20%) and the protein may not regain full biological activity.

Proteolytic Degradation

Recombinant MICB can be degraded by host proteases during expression or purification. Degradation is evident as multiple lower-molecular-weight bands on SDS-PAGE.

Solutions:

**Use protease-deficient E. coli strains** such as BL21(DE3) pLysS, which reduces basal expression and provides lysozyme to aid lysis
Add protease inhibitors to the lysis and purification buffers: 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 µg/mL leupeptin, 1 µg/mL pepstatin A, and 1 mM EDTA
Perform all purification steps at 4°C
Minimize the time between cell lysis and affinity chromatography
Use a C-terminal His₆ tag so that only full-length protein is captured; degraded fragments lacking the C-terminus will not bind the Ni-NTA resin

Other common issues include low yield due to poor codon adaptation (solve by gene synthesis with optimized codons), improper signal peptide cleavage (verify by N-terminal sequencing), and endotoxin contamination (remove using endotoxin removal columns such as Pierce High-Capacity Endotoxin Removal Resin).

Frequently Asked Questions

What is the best expression system for recombinant MICB protein?

The best system depends on the application. For structural studies requiring unglycosylated protein, E. coli is preferred due to high yield and cost-effectiveness. For functional assays, immunogen production, or therapeutic applications requiring authentic glycosylation, mammalian expression (HEK293 or CHO cells) is superior. If you require high-throughput screening of many MICB variants, E. coli is more practical. For a detailed comparison of expression hosts, see recombinant protein expression system.

Why is my recombinant MICB protein insoluble?

Insolubility in E. coli is almost always due to inclusion body formation. This occurs when protein synthesis outpaces folding. Reduce the induction temperature to 16–20°C, lower the IPTG concentration to 0.1–0.5 mM, and consider using a strain with oxidizing cytoplasm (Origami) or co-expressing chaperones. If the protein is expressed in the cytoplasm without a signal peptide, the reducing environment prevents disulfide bond formation, leading to misfolding. Secretion to the periplasm using a pelB signal peptide often improves solubility. See recombinant protein solubility expression for additional strategies.

How do I add a His-tag to MICB?

The His₆ tag is added at the DNA level. Design a forward or reverse primer that includes the sequence encoding six histidines (CATCACCATCACCATCAC) in frame with the MICB coding sequence. Alternatively, use a vector that already contains a His₆ tag, such as pET-28a (N-terminal tag) or pET-24a (C-terminal tag). For secreted proteins, a C-terminal tag is preferred to avoid interference with signal peptide cleavage.

What is the role of the signal peptide in MICB expression?

The signal peptide directs the nascent polypeptide to the secretory pathway. In E. coli, the pelB signal peptide targets the protein to the periplasm, where the oxidizing environment allows disulfide bond formation. In mammalian cells, the native MICB signal peptide or the IgG kappa leader directs the protein to the endoplasmic reticulum and subsequent secretion into the culture medium. Without a functional signal peptide, MICB is retained in the cytoplasm, where it is more likely to misfold and aggregate.

Can I express MICB in E. coli without a signal peptide?

Yes, but with caveats. Cytoplasmic expression without a signal peptide is simpler and can produce high yields, but the reducing environment of the cytoplasm prevents disulfide bond formation, and the protein is often insoluble. If you choose cytoplasmic expression, you may need to refold the protein from inclusion bodies. Alternatively, use an E. coli strain such as SHuffle or Origami that has an oxidizing cytoplasm to support disulfide bond formation.

How do I detect recombinant MICB after purification?

The most common methods are SDS-PAGE with Coomassie staining (to visualize the protein band), Western blot with an anti-MICB antibody (to confirm identity), and ELISA (to quantify the protein). For functional verification, an NKG2D binding assay using SPR or flow cytometry can confirm that the recombinant protein is biologically active.

What is the molecular weight of recombinant MICB?

The molecular weight depends on the expression system and the construct. The unglycosylated MICB ECD (amino acids 24–307) with a His₆ tag has a theoretical molecular weight of approximately 32–33 kDa, as calculated from the amino acid sequence. When expressed in mammalian cells, the addition of three N-linked glycans increases the apparent molecular weight to approximately 40–45 kDa on SDS-PAGE. Always verify the molecular weight empirically by SDS-PAGE and mass spectrometry.

Key Takeaways

MICB is a stress-induced NKG2D ligand with critical roles in immune surveillance; recombinant MICB is essential for studying NKG2D biology, developing diagnostic assays, and generating therapeutic antibodies.
Choose E. coli for high-yield, unglycosylated protein suitable for structural studies; choose mammalian cells for glycosylated, functionally authentic protein for cell-based assays.
Design the construct with a signal peptide (pelB for E. coli, native or IgG kappa for mammalian), the full extracellular domain (amino acids 24–307), and a C-terminal His₆ tag with a TEV protease cleavage site.
Codon optimization is essential for E. coli expression of human MICB; synthetic genes with optimized codons can increase yields by 5–10 fold.
Optimize expression by testing IPTG concentrations (0.1–1.0 mM) and temperatures (16–25°C); lower temperatures favor soluble expression.
Purify His-tagged MICB by Ni-NTA affinity chromatography followed by size-exclusion chromatography to remove aggregates and imidazole.
Verify protein identity and integrity by SDS-PAGE, Western blot with anti-MICB antibodies, and mass spectrometry.
Troubleshoot insolubility by reducing expression rate, using oxidizing E. coli strains, or switching to mammalian expression; address degradation with protease inhibitors and cold-room purification.
For complex projects requiring specialized expertise, consider contract recombinant protein expression or custom recombinant protein expression services.